About Ensemble

Leadership

JOHN RIPPLE
Chief Executive Officer

John Ripple joined Ensemble Therapeutics as Chief Executive Officer in 2013. Prior to Ensemble, John served as CEO at Permeon Biologics, Virdante Pharmaceuticals (acquired by Momenta Pharmaceuticals in 2011), and Syntonix Pharmaceuticals (acquired by Biogen Idec in 2007). He has held positions in business development at Syntonix, Wyeth Pharmaceuticals, and Genetics Institute. His other business experiences include medical device marketing and management consulting. John started his career as an aerospace engineer at NASA. He currently serves on the Board of Overseers at the Marine Biological Laboratory (Woods Hole, MA), as an advisor to the MIT Deshpande Center for Technological Innovation, and on the Board of Directors of the Children’s Melanoma Prevention Foundation.

John received a B.S. in Mechanical Engineering from Bucknell University and an M.B.A. from Harvard Business School.

STEPHEN P. HALE, Ph.D.
Chief Scientific Officer

Stephen Hale joined Ensemble Therapeutics in 2006. He is currently Senior Vice President, Biological Sciences and is responsible for advancing all in-house and partnered discovery programs. Ensemble’s in-house pipeline is oncology focused with a particular emphasis on the immune checkpoint and ubiquitin proteasome system (UPS) areas.

Prior to Ensemble, he was responsible for all biological aspects of the pre-clinical small molecule and peptidomimetic drug discovery programs at Praecis Pharmaceuticals. His role as a key inventor of the DNA-Encoded Library/Direct Select drug discovery platform and his involvement in the advancement of multiple pre-clinical candidate molecules in oncology were integral to the value generation that led to the acquisition of Praecis by GlaxoSmithKline plc.

Early in his career he was a founding scientist at Phylos Inc., where he had responsibilities in both the therapeutic and microarray areas. He was a leader in the development of a preclinical pipeline of protein therapeutics, namely antibodies and antibody-mimic molecules, and the concurrent development of diagnostic protein array products. He led the team responsible for the identification of a human fibronectin-based VEGF/KDR antagonist that was acquired and advanced into clinical development by Bristol Myers Squibb.

He has been a consultant to Cubist Pharmaceuticals and involved in early work at Genex Inc. on the design and engineering of single-chain antibodies for therapeutic and industrial applications. He has numerous publications in top-tier journals and is an inventor on 17 issued patents.

He received his Ph.D. in Biochemistry from the University of Maryland, College Park and was a NIH post-doctoral fellow at MIT under the direction of Dr. Paul Schimmel.